BioCentury
ARTICLE | Financial News

New IPO filings include Adaptive, Morphic

May 31, 2019 8:36 PM UTC

Immunosequencing company Adaptive and integrin company Morphic each filed for IPOs on NASDAQ Thursday, while antipsychotic therapy developer Karuna revealed details of its planned listing on the exchange on Friday.

Adaptive Biotechnologies Corp. (Seattle, Wash.) proposed to raise up to $230 million in an IPO underwritten by Goldman Sachs, J.P. Morgan, BofA Merrill Lynch, Cowen, Guggenheim, William Blair and BTIG. The company spun out of the Fred Hutchinson Cancer Research Center in 2009 and offers its immunoSEQ assay, a high throughput sequencing kit for T and B cell receptors, and clonoSEQ, a CLIA-certified laboratory-developed test (LDT) to monitor minimal residual disease in patients with blood-based cancers...